CompletedNo phase
A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- East Hanover, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 13 people enrolled
- Started
- 21 Jun 2023
- Ended
- 25 Feb 2025
- Type of study
- Observational
- Record updated
- 19 February 2026
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Male or female pediatric patients aged ≥2 years and <18 years at the time of initiating eltrombopag and IST treatment
- Subjects diagnosed with sAA and treated with eltrombopag in combination with IST as first-line therapy, based on the physician's decision in accordance with locally approved prescribing information at the time of data collection
- Subjects whose analytical index date (start date of eltrombopag administration) was at least 6 months prior to the data extraction date
Who cannot take part
- None
Where in United States
- NovartisEast Hanover, United StatesNo longer taking part
About the trial
What the trial wants to find out
The aim of this study was to investigate the safety, tolerability, and effectiveness of eltrombopag in combination with immunosuppressive therapy (IST) in real world practice in pediatric patients with severe aplastic anemia (sAA) in Korea. The study used data over a 6-month period extracted from patients' medical charts (electronic medical records) starting from the initiation of eltrombopag treatment.
The group in the trial
- Eltrombopag and IST Treatment Cohort
Pediatric patients with sAA who received first-line eltrombopag in combination with IST.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Retrospective Chart Review of Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia
- Record updated
- 19 February 2026